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Abstract
Summary A randomized placebo-controlled trial was con-
ducted to examine the effect of daily oral 1 mg minodronate
on vertebral fractures in 704 postmenopausal women with
established osteoporosis for 24 months. Minodronate
treatment reduced vertebral fractures by 59% without
serious adverse events. Minodronate is a safe and effective
bisphosphonate for osteoporosis treatment.
Introduction Minodronate increases bone mineral density
(BMD) in postmenopausal osteoporotic patients. However,
its efficacy in reducing osteoporotic fractures has not been
tested.
Methods To examine anti-fracture efficacy and safety of
daily oral minodronate in postmenopausal women with
established osteoporosis, a randomized, double-blind, pla-
cebo-controlled trial was conducted in 704 postmenopausal
women (55 to 80 years) with one to five vertebral fractures
and low BMD. Subjects were randomly assigned to receive
daily oral 1 mg minodronate (n=359) or placebo (n=345)
for 24 months, with daily supplements of 600 mg calcium
and 200 IU vitamin D3.
Results Daily 1 mg minodronate for 24 months reduced the
risk of vertebral fractures by 59% (95% CI, 36.6–73.3%).
Furthermore, when fractures during the first 6 months were
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Fukuoka, Japaneliminated, the risk of vertebral fractures from 6 to
24 months was reduced by 74% in minodronate-treated
group. Minodronate treatment also reduced height loss.
Bone turnover markers were suppressed by about 50% after
6 months of minodronate treatment and remained sup-
pressed thereafter. The overall safety profile including
gastrointestinal safety was similar between the two groups.
Conclusions Daily oral minodronate is safe, well-tolerated,
and is effective in reducing vertebral fracture risk in
postmenopausal women with established osteoporosis.
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Introduction
More than one fourth of women in their 70s suffer from at
least one osteoporotic vertebral fracture [1, 2]. Incidence of
new fractures rises with increasing number of preexisting
fractures [3], and not only morbidity but also mortality rate
rises with increasing number of fractures [4, 5]. Thus,
osteoporosis has become a significant socioeconomic
burden in aged societies.
Bisphosphonates have been shown to have potent anti-
fracture efficacy by inhibiting bone resorption, with a
reduction in bone turnover and an increase in bone mineral
density (BMD). Minodronate (ONO-5920/YM529) is a
nitrogen-containing bisphosphonate with potent inhibitory
effect on bone resorption [6]. Previous in vitro and in vivo
preclinical studies demonstrated that minodronate is about
ten times as potent as alendronate in inhibiting bone
resorption [7]. A randomized placebo-controlled double-
blind trial revealed that daily oral administration of 0.5, 1.0,
and 1.5 mg minodronate to Japanese women with post-
menopausal osteoporosis for 9 months caused an increase
in lumbar BMD by 4.9%, 5.7%, and 5.2%, respectively,
compared with the placebo group [8]. Because the
incidence of adverse gastrointestinal events did not increase
in a dose-dependent manner (0%, 12.6%, 6.3%, and 11.1%
by placebo, 0.5, 1.0, and 1.5 mg minodronate treatment,
respectively), minodronate was shown to be well tolerated
with excellent effect in increasing BMD. In addition, a
head-to-head comparison of the effects of daily oral 1 mg
minodronate with 5 mg alendronate revealed that the effect
of 12-month treatment with 1 mg minodronate on lumbar
and total hip BMD was similar to those of 5 mg alendronate
and that minodronate was generally well tolerated with
similar safety profiles to alendronate (Hagino et al.,
submitted for publication). These data suggest that minodr-
onate can become a new treatment choice as a potent
bisphosphonate for patients with established osteoporosis.
However, its efficacy in reducing osteoporotic fractures has
not been evaluated. The present phase III clinical trial was
conducted to examine the effect of daily oral 1 mg
minodronate on the prevention of vertebral fractures in
Japanese women with postmenopausal osteoporosis.
Materials and methods
Patient enrollment
We studied postmenopausal women aged 55 to 80 with one
to five fragility fractures between the vertebrae T4 and L4
and BMD below 80% (T score −1.7 at the lumbar spine) of
the young adult mean (YAM) [9]. Data for the YAM and T
score values were obtained from the reference data in 3,218
Japanese healthy women with 20 to 44 years of age [10].
Subjects were excluded if they had disorders such as
primary hyperparathyroidism, Cushing’s syndrome, prema-
ture menopause due to hypothalamic, pituitary or gonadal
insufficiency, poorly controlled diabetes mellitus (HbA1c
over 8.0%), or other causes of secondary osteoporosis, or if
they had any radiographic finding that might affect the
assessment of vertebral fractures and used hard or semi-
hard corset in spine part. Subjects with peptic ulcer were
excluded. Subjects were excluded if they had taken
bisphosphonates at any time. Subjects were also excluded
if they had taken glucocorticoids, calcitonin, vitamin K,
active vitamin D compounds, or hormone replacement
therapy within the previous 2 months, had serum calcium
(Ca) levels above 10.6 mg/dL (2.7 mmol/L) or below
8.0 mg/dl (2.0 mmol/L), had serum creatinine levels above
1.5 mg/dL (133 μmol/L), or had clinically significant
hepatic disorders.
This study was conducted in accordance with consider-
ation for the protection of patients, as outlined in the
Declaration of Helsinki, and was approved by the appro-
priate institutional review boards. All subjects gave written
informed consent before undergoing any examination or
study procedure, which was conducted in compliance with
Good Clinical Practice.
Study design
This study was a randomized, double-blind, placebo-
controlled, multicenter study at 98 sites in Japan.
Subjects who met all the entry criteria were enrolled
and sequentially assigned an allocation number inde-
pendent of study site. Subjects were randomized to take
1 mg minodronate (Astellas Pharma, Tokyo, Japan) or
placebo once a day and were treated for 24 months.
Randomization was performed by a computerized
system. Subjects were instructed to take their tablet on
rising and 30 min before food with plain water. All
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(200 IU) supplementation once a day after the evening
meal. Adherence with the study treatment was assessed
with the use of medication diaries and counts of
residual medication supplies.
Study outcomes
The primary endpoint of the study was the cumulative
proportion of patients with new morphometric vertebral
fractures at 24 months of treatment with the study
medication. Secondary endpoints included length of the
period to the occurrence of new vertebral fractures, the risk
of patients and length of the period to the occurrence of
clinical fractures, changes in height, and relative changes in
bone turnover markers.
Assessment of vertebral fractures Lateral radiographs of the
thoracic and lumbar spine were taken at the screening visit
to determine the presence of prevalent fractures. Subjects
were enrolled based on a visual assessment of prevalent
fractures in T4 to L4. All the radiologic specifications and
the levels of vertebra at the thoracic sand lumbar spine were
standardized throughout the study sites. The assessment of
prevalent fractures was made if the ratio of anterior or
middle vertebral body height to the posterior vertebral body
height was less than 0.8 [11]. Quantitative and semiquan-
titative techniques [12, 13] were used to identify incident
vertebral fractures for the purposes of the efficacy determi-
nation. Lateral radiographs of the spine were performed at
6, 12, 18, and 24 months for the assessment of incident
fractures. An incident of new vertebral fracture was
diagnosed if the anterior, posterior, or middle vertebral
height had decreased by at least 15% and by 4 mm in a
vertebra that was normal at baseline, or semiquantitatively
as a progress in grades [11]. Morphological diagnosis of
fractures was made by quantitative and semiquantitative
assessment of two evaluators who were blinded to the
sequence of films at two independent central reading
facilities at Tottori University, Yonago, Japan by Hagino,
H. and at the University of Occupational and Environmen-
tal Health, Fukuoka, Japan by Nakamura, T., with adjudi-
cation by a third investigator (Nakano,T. at Tamana Central
Hospital, Kumamoto, Japan) in the event of discrepant
results.
Assessment of non-vertebral fractures All non-vertebral
fractures were identified symptomatically as clinical frac-
tures, and only non-traumatic fractures assessed by inves-
tigators were reported. Suspected clinical fractures at six
non-vertebral sites (humerus, radius/ulna, subclavia, pelvis,
femur, and tibia/fibula) were adjudicated radiographically,
and only radiographically confirmed fractures were listed.
Assessment of bone turnover Serum and urine samples
were collected at baseline, 6, 12, 18, and 24 months for
measurement of bone turnover markers, including urinary
total deoxypyridinoline (DPD) measured by high-perfor-
mance liquid chromatography (SRL, Tokyo, Japan) [14]
after acid hydrolysis, urinary type I collagen N-telopeptide
(NTX; Osteomark, Ostex International, Seattle, WA, USA),
serum bone-specific alkaline phosphatase (BALP; Osteo-
links “BAP”, Quidel, San Diego, CA, USA), serum
osteocalcin (BGP-IRMA Mitsubishi; Mitsubishi Kagaku
Iatron, Tokyo, Japan), and serum 25-hydroxyvitamin D (25
(OH)D; 125I RIA Kit, DiaSorin Inc., Saluggia, Italy).
Study subjects were asked to visit study sites during the
morning, but it was not mandatory to visit in the fasting
state.
Assessment of adverse events All subjects were questioned
about adverse events (AEs) of treatment at each visit, and
all adverse events reported were analyzed regardless of the
investigators’ assessments of causality. The Medical Dic-
tionary for Regulatory Activities (MedDRA, Version 8.1J)
was used to categorize reported adverse events.
Statistical analysis All the data analyses were performed by
statisticians from Ono under the supervision and confirma-
tion of data analyses by one of the authors (Ohashi, Y.).
The intention-to-treat (ITT) population comprised all
patients who received at least one dose of study medication
and who attended at least one follow-up visit for any
observation of efficacies. The ITT population was used for
all fracture and height analyses. Safety analyses population
comprised all patients who received at least one dose of
study medication in either treatment group. A per-protocol
(PP) approach was used as a primary approach to analyze
the bone turnover markers because they can change rapidly
by protocol violations, interruption of study therapy, or
concurrent illness. The PP approach excluded protocol
violators who took less than 75% study drug, who took
prohibited medications during the course of the trial, or
who violated the protocol in a significant manner as
specified in the data analysis plan, and patients who took
study drug for less than 12 months. This population
included all patients in the ITT population, except those
with a protocol deviation deemed to have a significant
impact on the efficacy variables, i.e., major deviations
regarding the inclusion/exclusion criteria, patients with
insufficient compliance (<75% of the study medication),
documentation of forbidden concomitant medication that
could bias the fracture results, and patients lacking an
assessable baseline and follow-up for X-ray assessments for
less than 12 months.
The risk of patients with new morphometric vertebral
fractures at 24 months, as the primary endpoint, was
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group to the placebo group by the time-to-event curves
(Kaplan–Meier method), the event being the first new
incident vertebral fracture. The primary hypothesis was
tested using an ITT analysis that was modified to
include all subjects randomized, who had taken at least
one dose of study drug, and attended at least one
follow-up visit. A Cox regression model was used to
estimate the relative risk of vertebral fracture and its
95% confidence interval in minodronate group and
placebo group. Log-rank test was used to determine
the superiority of the minodronate group to the placebo
group. The power calculation was based on the
predictive risk of vertebral fracture. For the study to
achieve a power of 90% to detect the superiority, a
sample size of 290 subjects per group was required. To
allow for subject withdrawals, the intention was to
enroll 640 to 650 subjects. Differences were considered
to be statistically significant if the p value was less
than 0.05.
Group mean and standard error (SE) were given for the
percent changes from baseline in bone turnover markers
and changes from baseline in height and were used to
assess the significance of changes within two groups. T test
was used to determine whether minodronate group was
significantly different from the placebo group. The compa-
rability between minodronate and placebo groups for
demographic information was assessed with Wilcoxon’s
rank-sum test or Fisher’s exact test. Differences in
proportions of patients with AEs were analyzed using
Fisher’s exact test. The treatment groups were also
compared for the proportion of patients with gastrointesti-
nal AEs using Fisher’s exact test. Statistical analyses were
performed using Statistical Analysis Systems (SAS Insti-
tute, Cary, NC, USA). All protocol violators were identified
before database lock of the study.
Results
Patient disposition
A total of 1,083 subjects were screened at 98 study sites in
Japan (Fig. 1). A total of 704 subjects were randomized to
take either minodronate (359 subjects) or placebo (345
subjects). Five patients in the minodronate group and three
patients in the placebo group were excluded from the safety
analysis population for reasons of not receiving the study
medication or withdrawal of informed consent. Among the
safety analysis population, a total of 161 had been treated
with either 20 IU/week calcitonin (154 subjects) or estrogen
(seven subjects) before the washout period. None of the
study subjects were given glucocorticoid treatment before
enrollment. The proportion of the subjects in the ITT
analysis (95.5% and 95.9% in minodronate and placebo
groups, respectively) and PP analysis (75.5 and 76.2% in
minodronate and placebo groups, respectively) was similar
between the two groups.
Baseline characteristics of the subjects
The baseline demographics of subjects were well balanced
between the two groups (Table 1). The number of vertebral
fractures at baseline was not significantly different, and the
number of subjects with one, two, and three or more
vertebral fractures was similar between the two groups.
There was no significant difference in lumbar BMD, serum
25(OH)D, and the levels of bone turnover markers at the
baseline between the two groups.
Vertebral fractures
After 24 months of treatment, there was a statistically
significant reduction in the risk of vertebral fractures in the
minodronate group compared with the placebo group
(p<0.0001, log-rank test; Fig. 2). The Kaplan–Meier
estimates of risk after 24 months of treatment were 10.4%
in the minodronate group and 24.0% in the placebo group
of the ITT population. Relative risk of vertebral fractures by
minodronate treatment was 0.411 (95% confidence interval
[CI], 0.267–0.634), and relative risk reduction rate in
cumulative fracture incidence by minodronate treatment
was 59%. Among patients in the PP population who
completed the 2-year study (n=253 in the minodronate
group and n=239 in then placebo group), the incidence of
vertebral fractures was 9.9% in the minodronate group and
21.3% in the placebo group. These numbers were very
similar to those observed in the ITT population.
A large number of fractures occurred during the first
6 months in both groups (20 and 27 in minodronate and
placebo groups, respectively), and the decrease in vertebral
fracture risk by minodronate treatment was more pro-
nounced after the initial 6 months until the end of the study
period (Table 2). When the incidence of vertebral fractures
during the first 6 months was compared between subgroups
with one prevalent fracture and two or more fractures, the
incidence of vertebral fractures during the first 6 months
was five (3.5%) in minodronate group and six (4.3%) in
placebo group among patients with one prevalent fracture.
In contrast, vertebral fracture incidence during the first
6 months was 15 (9.0%) in the minodronate group and 21
(12.3%) in the placebo group among patients with two or
more prevalent fractures. Thus, majority of the fractures
during the early study period came from patients with two
or more prevalent fractures.
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In order to examine whether the effect of minodronate on
vertebral fracture prevention was related to the stature of
patients, height of studied subjects was assessed at 12 and
24 months using stature meter equipped at each study site.
At 12 months, a mean stature loss in the minodronate group
(1.2 mm) was already significantly less than that in the
placebo group (3.4 mm; p<0.05) (Fig. 3a). After 24 months
of treatment, a mean stature loss of 6.8 mm was observed in
the placebo group, which was significantly larger than that
in the minodronate group (3.7 mm, p<0.01; Fig. 3a). There
was no significant height loss in those patients without
fracture, and in those patients who did not fracture, no
significant effect of minodronate treatment on the height
was observed (Fig. 3b).
Non-vertebral fractures
Non-vertebral fractures that occurred during the trial were
picked up from the report of clinical fractures and
confirmed by radiographs. Because the number of subjects
in each group was small and the study period was short, no
significant difference was observed between the groups
Table 1 Demographics and baseline characteristics of subjects
Characteristic Minodronate (n=343) Placebo (n=331)
Age (years) 71.4 [6.0] 71.7 [5.6]
Height (cm) 147.6 [5.9] 147.0 [5.9]
Body mass index (kg/m
2) 23.4 [3.1] 23.5 [3.3]
Time since menopause (years) 21.3 [7.2] 22.2 [6.8]
Number of prevalent vertebral fractures 2.0 [1.2] 2.1 [1.2]
With one fracture [n (%)] 161 (46.9) 147 (44.4)
With two fractures [n (%)] 88 (25.7) 80 (24.2)
With three or more fractures [n (%)] 94 (27.4) 104 (31.4)
Lumbar BMD T score −2.95 [0.77] −2.95 [0.77]
Serum 25(OH)D (ng/mL) 25.0 [6.0] 25.4 [6.2]
Serum BALP (U/L) 33.0 [11.8] 33.4 [13.0]
Serum osteocalcin (ng/mL) 9.1 [2.8] 9.2 [3.1]
Urine total DPD (pmol/μmol Cr) 8.8 [3.6] 8.9 [3.1]
Urine NTX (nmol BCE/mmol Cr) 50.2 [24.0] 50.9 [21.9]
Data are means [SD] for the indicated number of subjects in each group.
Screened
n=1083
Patients not randomized
n=379
Randomized
n=704
Minodronate
n=359
Safety analysis
n=354 (98.6%)
ITT analysis
n=343 (95.5%)
PP analysis
n=271 (75.5%)
Completed 2 years
n=253 (70.5%)
Entry Criteria violation
Protocol violation
n=11
Voluntary Withdrawal
Adverse events
Protocol violation
Treatment failure 
Lost to follow up
n=72
Voluntary Withdrawal
Adverse events
n=18
Placebo
n=345
Safety analysis
n=342 (99.1%)
ITT analysis
n=331 (95.9%)
PP analysis
n=263 (76.2%)
Completed 2 years
n=239 (69.3%)
Entry Criteria violation
Protocol violation
n=11
Voluntary Withdrawal
Adverse events
Protocol violation
Treatment failure 
Lost to follow up
n=68
Voluntary Withdrawal
Adverse events
n=24
Fig. 1 Enrollment and
outcomes. A total of 1,083
subjects were screened, and 704
subjects were randomized to
take either minodronate
(359 subjects) or placebo (345
subjects)
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of non-vertebral fractures at the major six sites (radius/ulna,
humerus, femur, tibia/fibula, subclavia, and pelvis) after
24 months of treatment (2.7% in the minodronate and 3.5%
in the placebo group).
Bone turnover markers
Bone turnover markers decreased significantly in the
minodronate group, compared with in the placebo group
(p<0.0001). Mean percent changes in bone resorption
markers, urinary DPD and NTX, at 6 months were
−42.4% and −49.5%, respectively, in the minodronate
group, compared with −4.0% and −7.9%, respectively, in
the placebo group. Bone resorption markers remained
almost constant thereafter until 24 months of treatment,
when the reduction in urinary DPD and NTX in the
minodronate group was −37.1% and −56.7%, respectively
(Fig. 4a, b). Bone formation markers, BALP and osteocal-
cin, also decreased at 6 months by −46.2% and −45.5%,
respectively, in the minodronate group, compared with
−14.1% and −16.3%, respectively, in the placebo group.
Bone formation markers also remained almost constant
until 24 months of treatment, and reduction in BALP and
osteocalcin from baseline was −51.7% and −50.9% in the
minodronate group, respectively (Fig. 4c, d).
Adverse events
The overall incidence of AEs was similar in both groups, as
was the incidence of gastrointestinal AEs, drug-related
AEs, and serious AEs (Table 3). The most common
gastrointestinal tract AEs were constipation, gastric dis-
comfort, and diarrhea. Among serious AEs, more patients
in minodronate group reported infections/infestations and
cardiac disorders. Infections included two pneumonia
patients in both minodronate and placebo groups, and all
the other infections were reported in only one patient in
either group. Cardiac disorders included three patients in
minodronate and two patients in placebo group with
ischemic heart diseases, and one patient each with cardiac
insufficiency and sinus arrhythmia in minodronate group.
None of them reported atrial fibrillation. The proportion of
subjects who discontinued the study due to AEs was also
similar between the two groups. Complaints related to
digestive system were the most common AEs associated
with withdrawal from the study (Table 3).
Discussion
The present study demonstrated that daily oral administra-
tion of 1 mg minodronate for 24 months reduced the risk of
new vertebral fractures by 59% compared with that in the
placebo group. The effect of minodronate on vertebral
fracture was observed within 12 months, and there was also
a significant decrease in height loss at 12 months. The
overall safety profile including gastrointestinal safety was
similar between the two groups.
Table 2 Cumulative incidence of vertebral fractures
Months Minodronate Placebo Log-rank
test
n Number of
patients (%)
Cumulative
incidence (%)
n Number of
patients (%)
Cumulative
incidence (%)
0 339 0 (0.0) 0.0 328 0 (0.0) 0.0 P<0.0001
6 310 20 (6.5) 6.5 308 27 (8.7) 8.7
12 274 1 (0.4) 6.8 265 11 (4.2) 12.5
18 261 6 (2.3) 8.9 242 14 (5.8) 17.6
24 246 4 (1.6) 10.4 219 17 (7.8) 24.0
Data was analyzed by actuarial method.
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Fig. 2 Kaplan–Meier estimates of the effect of daily oral 1 mg
minodronate for 24 months on the risk of vertebral fractures in
osteoporotic subjects. Cumulative incidence of vertebral fractures
from the start of the study. Minodronate treatment reduced relative risk
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1434 Osteoporos Int (2009) 20:1429–1437In the present study, a large number of vertebral fractures
occurred during the first 6 months in both groups (20 and
27 in minodronate and placebo groups, respectively). In our
previous study, to compare the effect of minodronate on
lumbar BMD and bone markers with that of alendronate
(Hagino et al., submitted for publication), bone resorption
markers were suppressed within 1 month, and lumbar BMD
was significantly increased after 3 months of minodronate
treatment. It should be noted that the assessment of
vertebral fractures at baseline was performed within
2 months before the start of study drug administration.
Therefore, a part of vertebral fractures identified after
6 months of drug administration might have occurred
before drug administration was started. Although the exact
reason why a large number of vertebral fractures occurred
during the early period in both groups remains unclear,
minodronate showed a marked anti-fracture efficacy from 6
to 24 months of treatment (Table 2).
In contrast to the robust inhibitory effect on vertebral
fractures, the present study did not show a significant effect
of minodronate in reducing non-vertebral fractures. This is
a major limitation of the present study. Because the study
was aimed to examine the ability of minodronate to reduce
the risk of vertebral fractures, the study did not have
enough power in terms of the number of study subjects and
the length of study period to examine the effect of
minodronate on non-vertebral fractures. Thus, although
the study included patients with established osteoporosis
having at least one prevalent vertebral fracture, the number
of non-vertebral fractures developed in long bones during
the 24-month study period was too small to draw any
conclusions.
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significant difference was observed between the minodro-
nate and placebo groups in any AEs including drug-related
or serious AEs. Although the most common AEs were
gastrointestinal AEs, the incidence of gastrointestinal AEs,
as well as those that caused discontinuation from the study,
was very similar between the minodronate and placebo
groups. These results suggest that minodronate does not
cause any serious disturbance in osteoporotic patients, and
daily administration of minodronate can be well-tolerated in
patients with osteoporosis.
Minodronate exhibits very similar antiresorptive potency
to zoledronic acid in pre-clinical studies [7], and intermit-
tent oral administration of ibandronate [15] as well as
yearly intravenous administration of zoledronic acid [16]
demonstrated potent anti-fracture efficacy. Therefore, fur-
ther studies are warranted to examine the effect of
intermittent oral and intravenous minodronate on vertebral
and non-vertebral fractures in osteoporotic patients.
In conclusion, daily oral minodronate is safe, well-
tolerated, and is effective in reducing vertebral fracture risk
in postmenopausal women with established osteoporosis.
Because the dose of minodronate in reducing fracture
incidence was low, further studies are warranted to evaluate
the efficacy of intermittent administration of higher doses
of minodronate on osteporotic fractures.
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Hospital; Y. Nagasaka, Nagasaka Orthopedics; M. Suzuki, Suzuki
Orthopedic Iin; S. Kumaki, Hokushin General Hospital; S. Kobayashi,
Shinsyu University Hospital; T. Hanaoka, Yamabe Spa Hanaoka
Table 3 Summary of adverse events
Minodoronate, n (%) Placebo, n (%)
No. of patients 354 342
Any AE 334 (94.4) 327 (95.6)
Gastrointestinal AE 173 (48.9) 155 (45.3)
“Drug-related” AE
a 57 (16.1) 54 (15.8)
Serious AE
b 49 (13.8) 65 (19.0)
Injury, poisoning and procedural complications 10 (2.8) 13 (3.8)
Musculoskeletal and connective tissue disorders 8 (2.3) 9 (2.6)
Gastrointestinal disorders 7 (2.0) 9 (2.6)
Nervous system disorders 4 (1.1) 10 (2.9)
Infections and infestations 7 (2.0) 3 (0.9)
Eye disorders 1 (0.3) 8 (2.3)
Respiratory, thoracic and mediastinal disorders 3 (0.8) 5 (1.5)
Cardiac disorders 5 (1.4) 2 (0.6)
Neoplasms benign, malignant and unspecified 2 (0.6) 4 (1.2)
Discontinued due to AE 55 (15.5) 47 (13.7)
Discontinued due to gastrointestinal AE 17 (4.8) 13 (3.8)
Discontinued due to “drug-related” AE 17 (4.8) 14 (4.1)
Data are number of patients
AE adverse event
aAEs reported as drug-related by the investigators are listed as “drug-related”
bSerious AEs with more than two patients in either treatment group are listed
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